Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection.
O V MaltsevK V KasyanenkoK V KozlovK V ZhdanovI I LapikovPublished in: Terapevticheskii arkhiv (2022)
The use of riamilovir for the treatment of patients with moderate novel coronavirus infection (COVID-19) resulted in a significant reduction of general infectious syndromes and respiratory symptoms. Patients from the experimental group significantly faster achieved clinical recovery and sanitation from the pathogen according to the results of NAAT diagnostics.